{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:40:27Z","timestamp":1790746827294,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ole Jacobsen Commemoration Foundation"},{"name":"The Region of Southern Denmark Health Research Fund"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.jns.2014.01.019","type":"journal-article","created":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T17:45:38Z","timestamp":1389980738000},"page":"52-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antibodies against interferon-beta in neuromyelitis optica patients"],"prefix":"10.1016","volume":"339","author":[{"given":"Nasrin","family":"Asgari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten Ohm","family":"Kyvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troels","family":"Steenstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egon","family":"Stenager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soeren Thue","family":"Lillevang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2014.01.019_bb0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2007.04.009","article-title":"Neuromyelitis optica: changing concepts","volume":"187","author":"Jacob","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2014.01.019_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0404.2010.01416.x","article-title":"Neuromyelitis optica (NMO) \u2014 an autoimmune disease of the central nervous system (CNS)","volume":"123","author":"Asgari","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jns.2014.01.019_bb0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic\u2013spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jns.2014.01.019_bb0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1155\/2006\/586306","article-title":"NMO-IgG: a specific biomarker for neuromyelitis optica","volume":"22","author":"Weinshenker","year":"2006","journal-title":"Dis Markers"},{"key":"10.1016\/j.jns.2014.01.019_bb0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev.med.50.1.291","article-title":"Immunologic therapy of multiple sclerosis","volume":"50","author":"Arnason","year":"1999","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jns.2014.01.019_bb0030","doi-asserted-by":"crossref","first-page":"pe70","DOI":"10.1126\/stke.4162007pe70","article-title":"Type I interferons as anti-inflammatory mediators","volume":"2007","author":"Benveniste","year":"2007","journal-title":"Sci STKE"},{"key":"10.1016\/j.jns.2014.01.019_bb0035","first-page":"1480","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012"},{"key":"10.1016\/j.jns.2014.01.019_bb0040","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2014.01.019_bb0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000227277","article-title":"Interferon-beta(1b) treatment in neuromyelitis optica","volume":"62","author":"Tanaka","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jns.2014.01.019_bb0050","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/1531-8249(200011)48:5<706::AID-ANA3>3.0.CO;2-V","article-title":"Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group","volume":"48","author":"Ross","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2014.01.019_bb0055","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/WNL.52.6.1239","article-title":"Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies","volume":"52","author":"Deisenhammer","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.01.019_bb0060","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1212\/WNL.50.5.1266","article-title":"Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"50","author":"Rudick","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.01.019_bb0065","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1468-1331.2005.01386.x","article-title":"Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis","volume":"12","author":"Sorensen","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2014.01.019_bb0070","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"A population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.01.019_bb0075","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.01.019_bb0080","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.01.019_bb0085","first-page":"39","article-title":"Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis","volume":"12","author":"Ross","year":"2006"},{"key":"10.1016\/j.jns.2014.01.019_bb0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/jir.2007.0142","article-title":"Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene","volume":"28","author":"Lallemand","year":"2008","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jns.2014.01.019_bb0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/jir.2012.0027","article-title":"Cell-based reporter gene assay for therapy-induced neutralizing antibodies to interferon-beta in multiple sclerosis","volume":"33","author":"Martins","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jns.2014.01.019_bb0100","first-page":"23","article-title":"HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica","volume":"18","author":"Asgari","year":"2012"},{"key":"10.1016\/j.jns.2014.01.019_bb0105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","article-title":"Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis","volume":"298","author":"Jarius","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2014.01.019_bb0110","first-page":"108","article-title":"Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy","volume":"18","author":"Barnett","year":"2012"},{"key":"10.1016\/j.jns.2014.01.019_bb0115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2014.01.019_bb0120","first-page":"113","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012"},{"key":"10.1016\/j.jns.2014.01.019_bb0125","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1007\/s00415-012-6829-3","article-title":"The impact of neutralizing antibodies on the risk of disease worsening in interferon beta-treated relapsing multiple sclerosis: a 5year post-marketing study","volume":"260","author":"Paolicelli","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2014.01.019_bb0130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2014.01.019_bb0135","first-page":"1067","article-title":"Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders","volume":"17","author":"Jarius","year":"2011"},{"key":"10.1016\/j.jns.2014.01.019_bb0140","first-page":"5","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012"},{"key":"10.1016\/j.jns.2014.01.019_bb0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.0105-2896.2005.00219.x","article-title":"The role of BAFF in immune function and implications for autoimmunity","volume":"204","author":"Kalled","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jns.2014.01.019_bb0150","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.20041674","article-title":"BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma","volume":"201","author":"Krumbholz","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jns.2014.01.019_bb0155","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nm.2110","article-title":"T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis","volume":"16","author":"Axtell","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jns.2014.01.019_bb0160","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/brain\/awp228","article-title":"A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis","volume":"132","author":"Comabella","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.jns.2014.01.019_bb0165","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.jns.2014.01.019_bb0170","doi-asserted-by":"crossref","first-page":"8274","DOI":"10.4049\/jimmunol.179.12.8274","article-title":"IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice","volume":"179","author":"Smith","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jns.2014.01.019_bb0175","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jneuroim.2007.01.011","article-title":"Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response","volume":"185","author":"Graber","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2014.01.019_bb0180","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00207450903428970","article-title":"Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients","volume":"120","author":"Icoz","year":"2010","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.jns.2014.01.019_bb0185","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/brain\/awh453","article-title":"Intrathecal activation of the IL-17\/IL-8 axis in opticospinal multiple sclerosis","volume":"128","author":"Ishizu","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.jns.2014.01.019_bb0190","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.expneurol.2013.02.005","article-title":"Neuromyelitis optica-like pathology is dependent on type I interferon response","volume":"247","author":"Khorooshi","year":"2013","journal-title":"Exp Neurol"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14000434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14000434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T03:54:13Z","timestamp":1538884453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X14000434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":38,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0022510X14000434"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2014.01.019","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibodies against interferon-beta in neuromyelitis optica patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2014.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}